Provided is a kind of modified recombinant human endostatin that has the structure of CH 3 O-(CH 2 CH 2 O) m -CH 2 CH 2 CH 2 -N ± H-Endostar, wherein the average molecular weight of CH 3 O-(CH 2 CH 2 O) m -CH 2 CH 2 CH 2 is 20-40kD. The modified recombinant human endostatin enhances the stability in vivo, improves blood drug concentration, prolongs half-life, markedly increases the activity of inhibiting the endothelial cells proliferation, thus reduces drug dosage and decreases administration frequency. Its application for preparing anti-tumor pharmaceutical compositions is also provided.
